Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression

María Laura Polo, Marina Riggio, María May, María Jimena Rodríguez, María Cecilia Perrone, Melody Stallings-Mann, Diego Kaen, Marlene Frost, Matthew Philip Goetz, Judy C Boughey, Claudia Lanari, Derek C Radisky, Virginia Novaro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Improved efficacy of neoadjuvant endocrine-targeting therapies in luminal breast carcinomas could be achieved with optimal use of pathway targeting agents. In a mouse model of ductal breast carcinoma we identify a tumor regressive stromal reaction that is induced by neoadjuvant endocrine therapy. This reparative reaction is characterized by tumor neovascularization accompanied by infiltration of immune cells and carcinoma-associated fibroblasts that stain for phosphorylated ribosomal protein S6 (pS6), downstream the PI3K/Akt/mTOR pathway. While tumor variants with higher PI3K/Akt/mTOR activity respond well to a combination of endocrine and PI3K/Akt/mTOR inhibitors, tumor variants with lower PI3K/Akt/mTOR activity respond more poorly to the combination therapy than to the endocrine therapy alone, associated with inhibition of stromal pS6 and the reparative reaction. In human breast cancer xenografts we confirm that such differential sensitivity to therapy is primarily determined by the level of PI3K/Akt/mTOR in tumor cells. We further show that the clinical response of breast cancer patients undergoing neoadjuvant endocrine therapy is associated with the reparative stromal reaction. We conclude that tumor level and localization of pS6 are associated with therapeutic response in breast cancer and represent biomarkers to distinguish which tumors will benefit from the incorporation of PI3K/Akt/mTOR inhibitors with neoadjuvant endocrine therapy.

Original languageEnglish (US)
Pages (from-to)22081-22097
Number of pages17
JournalOncotarget
Volume6
Issue number26
StatePublished - 2015

Fingerprint

Phosphatidylinositol 3-Kinases
Breast Neoplasms
Neoadjuvant Therapy
Neoplasms
S 6
Therapeutics
Ribosomal Protein S6
Carcinoma, Ductal, Breast
Tumor Biomarkers
Heterografts
Proteins
Coloring Agents
Fibroblasts
Carcinoma

Keywords

  • Breast cancer
  • Neoadjuvant endocrine therapy
  • PI3K/Akt pathway
  • Tumor stroma

ASJC Scopus subject areas

  • Oncology

Cite this

Polo, M. L., Riggio, M., May, M., Rodríguez, M. J., Perrone, M. C., Stallings-Mann, M., ... Novaro, V. (2015). Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget, 6(26), 22081-22097.

Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. / Polo, María Laura; Riggio, Marina; May, María; Rodríguez, María Jimena; Perrone, María Cecilia; Stallings-Mann, Melody; Kaen, Diego; Frost, Marlene; Goetz, Matthew Philip; Boughey, Judy C; Lanari, Claudia; Radisky, Derek C; Novaro, Virginia.

In: Oncotarget, Vol. 6, No. 26, 2015, p. 22081-22097.

Research output: Contribution to journalArticle

Polo, ML, Riggio, M, May, M, Rodríguez, MJ, Perrone, MC, Stallings-Mann, M, Kaen, D, Frost, M, Goetz, MP, Boughey, JC, Lanari, C, Radisky, DC & Novaro, V 2015, 'Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression', Oncotarget, vol. 6, no. 26, pp. 22081-22097.
Polo ML, Riggio M, May M, Rodríguez MJ, Perrone MC, Stallings-Mann M et al. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget. 2015;6(26):22081-22097.
Polo, María Laura ; Riggio, Marina ; May, María ; Rodríguez, María Jimena ; Perrone, María Cecilia ; Stallings-Mann, Melody ; Kaen, Diego ; Frost, Marlene ; Goetz, Matthew Philip ; Boughey, Judy C ; Lanari, Claudia ; Radisky, Derek C ; Novaro, Virginia. / Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. In: Oncotarget. 2015 ; Vol. 6, No. 26. pp. 22081-22097.
@article{1a537b28388b487fa2f76e132c79b163,
title = "Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression",
abstract = "Improved efficacy of neoadjuvant endocrine-targeting therapies in luminal breast carcinomas could be achieved with optimal use of pathway targeting agents. In a mouse model of ductal breast carcinoma we identify a tumor regressive stromal reaction that is induced by neoadjuvant endocrine therapy. This reparative reaction is characterized by tumor neovascularization accompanied by infiltration of immune cells and carcinoma-associated fibroblasts that stain for phosphorylated ribosomal protein S6 (pS6), downstream the PI3K/Akt/mTOR pathway. While tumor variants with higher PI3K/Akt/mTOR activity respond well to a combination of endocrine and PI3K/Akt/mTOR inhibitors, tumor variants with lower PI3K/Akt/mTOR activity respond more poorly to the combination therapy than to the endocrine therapy alone, associated with inhibition of stromal pS6 and the reparative reaction. In human breast cancer xenografts we confirm that such differential sensitivity to therapy is primarily determined by the level of PI3K/Akt/mTOR in tumor cells. We further show that the clinical response of breast cancer patients undergoing neoadjuvant endocrine therapy is associated with the reparative stromal reaction. We conclude that tumor level and localization of pS6 are associated with therapeutic response in breast cancer and represent biomarkers to distinguish which tumors will benefit from the incorporation of PI3K/Akt/mTOR inhibitors with neoadjuvant endocrine therapy.",
keywords = "Breast cancer, Neoadjuvant endocrine therapy, PI3K/Akt pathway, Tumor stroma",
author = "Polo, {Mar{\'i}a Laura} and Marina Riggio and Mar{\'i}a May and Rodr{\'i}guez, {Mar{\'i}a Jimena} and Perrone, {Mar{\'i}a Cecilia} and Melody Stallings-Mann and Diego Kaen and Marlene Frost and Goetz, {Matthew Philip} and Boughey, {Judy C} and Claudia Lanari and Radisky, {Derek C} and Virginia Novaro",
year = "2015",
language = "English (US)",
volume = "6",
pages = "22081--22097",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression

AU - Polo, María Laura

AU - Riggio, Marina

AU - May, María

AU - Rodríguez, María Jimena

AU - Perrone, María Cecilia

AU - Stallings-Mann, Melody

AU - Kaen, Diego

AU - Frost, Marlene

AU - Goetz, Matthew Philip

AU - Boughey, Judy C

AU - Lanari, Claudia

AU - Radisky, Derek C

AU - Novaro, Virginia

PY - 2015

Y1 - 2015

N2 - Improved efficacy of neoadjuvant endocrine-targeting therapies in luminal breast carcinomas could be achieved with optimal use of pathway targeting agents. In a mouse model of ductal breast carcinoma we identify a tumor regressive stromal reaction that is induced by neoadjuvant endocrine therapy. This reparative reaction is characterized by tumor neovascularization accompanied by infiltration of immune cells and carcinoma-associated fibroblasts that stain for phosphorylated ribosomal protein S6 (pS6), downstream the PI3K/Akt/mTOR pathway. While tumor variants with higher PI3K/Akt/mTOR activity respond well to a combination of endocrine and PI3K/Akt/mTOR inhibitors, tumor variants with lower PI3K/Akt/mTOR activity respond more poorly to the combination therapy than to the endocrine therapy alone, associated with inhibition of stromal pS6 and the reparative reaction. In human breast cancer xenografts we confirm that such differential sensitivity to therapy is primarily determined by the level of PI3K/Akt/mTOR in tumor cells. We further show that the clinical response of breast cancer patients undergoing neoadjuvant endocrine therapy is associated with the reparative stromal reaction. We conclude that tumor level and localization of pS6 are associated with therapeutic response in breast cancer and represent biomarkers to distinguish which tumors will benefit from the incorporation of PI3K/Akt/mTOR inhibitors with neoadjuvant endocrine therapy.

AB - Improved efficacy of neoadjuvant endocrine-targeting therapies in luminal breast carcinomas could be achieved with optimal use of pathway targeting agents. In a mouse model of ductal breast carcinoma we identify a tumor regressive stromal reaction that is induced by neoadjuvant endocrine therapy. This reparative reaction is characterized by tumor neovascularization accompanied by infiltration of immune cells and carcinoma-associated fibroblasts that stain for phosphorylated ribosomal protein S6 (pS6), downstream the PI3K/Akt/mTOR pathway. While tumor variants with higher PI3K/Akt/mTOR activity respond well to a combination of endocrine and PI3K/Akt/mTOR inhibitors, tumor variants with lower PI3K/Akt/mTOR activity respond more poorly to the combination therapy than to the endocrine therapy alone, associated with inhibition of stromal pS6 and the reparative reaction. In human breast cancer xenografts we confirm that such differential sensitivity to therapy is primarily determined by the level of PI3K/Akt/mTOR in tumor cells. We further show that the clinical response of breast cancer patients undergoing neoadjuvant endocrine therapy is associated with the reparative stromal reaction. We conclude that tumor level and localization of pS6 are associated with therapeutic response in breast cancer and represent biomarkers to distinguish which tumors will benefit from the incorporation of PI3K/Akt/mTOR inhibitors with neoadjuvant endocrine therapy.

KW - Breast cancer

KW - Neoadjuvant endocrine therapy

KW - PI3K/Akt pathway

KW - Tumor stroma

UR - http://www.scopus.com/inward/record.url?scp=84941241926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941241926&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 22081

EP - 22097

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -